Small molecule inhibitors of NONO and other LLPS-associated proteins could be a potent therapeutic strategy for inhibiting the activation of the EGFR pathway and sensitizing cancer cells to conventional therapies [30, 31–32]. This evidence concerns the gene EGFR and cancer.